

CURRICULUM VITAE
DANIELE VERITTI

PERSONAL DATA

Name: Daniele Veritti

Birth date: [REDACTED]

Birth place: [REDACTED]

Citizenship: [REDACTED]

Marital status: [REDACTED]

CONTACT

[REDACTED]
[REDACTED]
[REDACTED]

CURRENT POSITION

Assistant Professor

*Department of Medical and Biological Sciences - Ophthalmology,
University of Udine, Udine, Italy*

From October 2013

PAST POSITIONS

Temporary Research Fellow

*Department of Medical and Biological Sciences - Ophthalmology,
University of Udine, Udine, Italy*

July 2012-September 2013

EDUCATION AND TRAINING

VENICE OPHTHALMOLOGY SUMMER SCHOOL

Venice, Italy

July 2013

EUROPEAN SCHOOL FOR ADVANCED STUDIES IN OPHTHALMOLOGY

*Retinal Diseases Module: Medical Retina and Surgical Retina
Lugano, Switzerland*

June 2010

RESIDENCY IN OPHTHALMOLOGY

Department of Ophthalmology, University of Udine, Udine, Italy

2008-2012

Thesis: "Triple Therapy for Anti-VEGF Non-responders in Neovascular Age-Related Macular Degeneration. Ranibizumab, Juxtascleral Triamcinolone Acetonide and Photodynamic therapy with verteporfin". Maximum grades and honours.

M.D. DEGREE

University of Udine, Udine, Italy

October 2007

Thesis: "Posterior Juxtascleral Infusion of Modified Triamcinolone Acetonide Formula-tion For Refractory Diabetic Macular Edema. One-year Follow Up"

INTERNSHIP IN OPHTHALMOLOGY

Department of Ophthalmology, University of Udine, Udine, Italy

2004-2007

HIGH SCHOOL DEGREE

Liceo scientifico "Luigi Magrini", Gemona del Friuli (Udine), Italy

2000

Thesis title: "Gravitational Lenses: Mirages in the Cosmos"

PUBLICATIONS

Bibliometric Indicators (Scopus 18.04.2016)

Number of documents: 38

Number of citations: 188

H index: 8

Peer Reviewed Journals

Lanzetta P, Monaco P, **Veritti D**. In reply to: Metha S. Major ocular complications after organ transplantation. Indian J Ophthalmol. 2004; 52:255-6.

Lanzetta P, Polito A, **Veritti D**. Subthreshold laser. Ophthalmology. 2008; 115:216-216e1.

Lanzetta P, Furlan F, Morgante L, **Veritti D**, Bandello F. Nonvisible Subthreshold Micropulse Diode Laser (810 nm) Treatment of Central Serous Chorioretinopathy. A Pilot Study. Eur J Ophthalmol. 2008; 18:934-40.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D, Lanzetta P, Perissin L, Bandello F. Posterior Juxtasclear Infusion of Modified Triamcinolone Acetonide Formulation for Refractory Diabetic Macular Edema. One-Year Follow Up. *Invest Ophthalmol vis Sci*. 2009; 50:2391-7.

Veritti D, Lanzetta P, Bandello F, Gortana Chiodini R. Viscoelastic Agent Retention and Failed Macular Hole Surgery. Retinal cases & brief reports. 2009; 3:77-9.

Bandello F, Battaglia Parodi M, Lanzetta P, Locwenstein A, Massin P, Menchini F, **Veritti D**. Diabetic Macular Edema. *Dev Ophthalmol*. 2010; 47:73-110.

Veritti D, Sarao V, Lanzetta P. Update on Combination Therapy in Wet Age-related Macular Degeneration. *Exp Rev Ophthalmol*. 2010;5:681-688.

Veritti D, Perissin L, Zorzet S, Lanzetta P. The Effect of Triamcinolone Acetonide, Sodium Hyaluronate, and Chondroitin Sulfate on Human Endothelial Cells: an in Vitro Study. *Eur J Ophthalmol*. 2010; S6:75-9.

Sheth S, Lanzetta P, **Veritti D**, Zucchiatti I, Savorgnani C, Bandello F. Experience with the Pascal® photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement. *Indian J Ophthalmol*. 2011 Mar-Apr;59(2):87-91.

Veritti D, Vergallo S, Lanzetta P. Triple therapy for corneal neovascularization: a case report. *Eur J Ophthalmol*. 2012; 22:S126-8.

Veritti D, Toneatto G, Lanzetta P. Low-concentration indocyanine green-assisted internal limiting membrane peeling in idiopathic macular pucker 25-gauge surgery. *Eur J Ophthalmol*. 2012; 22:626-34.

Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. *Expert Opin Drug Saf*. 2012; 11:331-40.

Veritti D, Sarao V, Lanzetta P. Online optical coherence tomography during subthreshold laser irradiation. *Eur J Ophthalmol*. 2012; 22:575-9.

Sarao V, **Veritti D**, Lanzetta P. Triamcinolone acetonide for the treatment of diabetic macular edema. *Europ Endocrinology*. 2012; 3:42-47.

Veritti D, Sarao V, Lanzetta P. Neovascular Age-Related Macular Degeneration. *Ophthalmologica*. 2012; 227:11-20.

Veritti D, Macor S, Menchini F, Lanzetta P. Effects of VEGF inhibition on retinal morphology, neovascular network size and visual acuity in patients with vascularized pigment epithelium detachment because of occult choroidal neovascularization. *Retina*. 2013; 33:982-9.

Veritti D, Sarao V, Lanzetta P. Bevacizumab and Triamcinolone Acetonide for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Anti-VEGFs. *J Ocul Pharmacol Ther*. 2013; 29:437-41.

Sarao V, **Veritti D**, Prosperi R, Pignatto S, Lanzetta P. A case of CRB1 negative Coats-like retinitis pigmentosa. *JAAPOS*. 2013; 17:414-6.

Sarao V, **Veritti D**, Lanzetta P. Regression of diabetic macular edema after subcutaneous exenatide. *Acta Diabetol*. 2014; 51:505-8.

Lanzetta P, Mitchell P, Wolf S, **Veritti D**. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. *Br J Ophthalmol*. 2013; 97:1497-507.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D, Lanzetta P. Triple Therapy for Anti-Vascular Endothelial Growth Factor Nonresponders in Neovascular Age-Related Macular Degeneration: Impact of Different Photodynamic Therapy Parameters. *Ophthalmologica*. 2013; 230:131-7.

Lanzetta P, Holz F, Monés J, Querques G, Stanga P, **Veritti D**, Barbone F, Brusaferro S, Isola M. Intravitreal Injections: A Healthcare Failure Modes and Effects Analysis. *Ophthalmologica*. 2013; 230:151-64.

Sarao V, Bertoli F, **Veritti D**, Lanzetta P. Pharmacotherapy for treatment of retinal vein occlusion. *Expert Opin Pharmacother*. 2014; 5:1-12.

Sarao V, **Veritti D**, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. *ScientificWorldJournal*. 2014; 8:2014:989501.

Gabai A, **Veritti D**, Lanzetta P. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting. *Eur J Ophthalmol*. 2014; 24:396-401.

Santarelli M, **Veritti D**, Dal Mas G, Lanzetta P. Functional and morphological changes after macular pucker surgery: an optical coherence tomography and microperimetric study. *Ophthalmologica*. 2014; 232:200-6.

Veritti D, Macor S, Lanzetta P. Early effects of dexamethasone implant on macular morphology and visual function in patients with macular edema secondary to retinal vein occlusion. *Ophthalmologica*. 2014; 232:144-8.

Sarao V, Bertoli F, **Veritti D**, Lanzetta P. Pharmacotherapy for treatment of retinal vein occlusion. *Expert Opin Pharmacother*. 2014; 15:2373-84.

Santarelli M, Diplotti L, Samassa F, **Veritti D**, Kuppermann BD, Lanzetta P. Advances in pharmacotherapy for wet age-related macular degeneration. *Expert Opin Pharmacother*. 2015; 16:1769-81.

Gabai A, **Veritti D**, Lanzetta P. Fundus autofluorescence applications in retinal imaging. *Indian J Ophthalmol*. 2015; 63:406-15.

Sarao V, **Veritti D**, Macor S, Lanzetta P. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. *Graefes Arch Clin Exp Ophthalmol*. 2016; 254:445-54.

Chhablani J, Bansal R, **Veritti D**, Sambhana S, Sarao V, Pichi F, Garrai R, Massaro D, Lembo A, Mansour AM, Banker A, Gupta SR, Hamani R, Lanzetta P. Dexamethasone implant in diabetic macular edema in real-life situations. *Eye (Lond)*. 2016; 30:426-30.

Sarao V, Parravano M, **Veritti D**, Arias L, Varano M, Lanzetta P. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. *Retina*. 2016; 36:770-7.

Book chapters

Antonutto G, **Veritti D**, Lanzetta P, Melato M. Occhio. In: Mariuzzi GM, ed. *Anatomia Patologica e Correlazioni Anatomico-Cliniche*. 1st ed. Padova, Italy: Piccin; 2006; vol 2: 2489-521.

Veritti D, Lanzetta P. Ocular complications after hand transplantation. In: Lanzetta M, Dubernard JM, eds. *Hand Transplantation*. 1st ed. Milan, Italy: Springer; 2006:241-6.

CURRICULUM VITAE
DANIELE VERITTI

Polito A, **Veritti D**, Lanzetta P. Non-proliferative diabetic retinopathy. In: Agarwal A, ed. Fundus Fluorescein and Indocyanine Green Angiography: A Textbook and Atlas. 1st ed. Thorofare, NJ: Slack Inc; 2008; chapter 24; 201-6.

Veritti D. Terapia combinata con ranibizumab e verteporfina. In: Lanzetta P, ed. Terapia anti-angiogenica in oftalmologia - casi clinici. Torino, Italy: Ellebore sas; 2009; chapter 7; 33-40.

Veritti D, Sborgia G, Boscia F, Smaldone G, Lanzetta P. Trauma and emergencies. In: Agarwal A, ed. Color atlas of ophthalmology. New York: Thieme; 2009; chapter 1; 1-32.

Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, **Veritti D**. Diabetic Macular Edema. In: Coscas G, ed. Macular edema. A practical approach. Basel: Karger; 2010; 73-110.

Lanzetta P, **Veritti D**, Dal Mas G, Sarao V. Macular pucker. In: Saxena S, Meyer CH, Ohji M, Akduman L, eds. Vitreoretinal Surgery. Daryaganj: Jaypee Brothers; 257-75.

Pignatto S, **Veritti D**, Gabai A, Lanzetta P. Selective laser trabeculoplasty. In: Gunvant P, ed. Glaucoma - Current Clinical and Research Aspects. Rijeka: In Tech; 2011; 257-72.

Other publications

Veritti D, Lanzetta P. La degenerazione maculare legata all'età. Scheda allegata a Sole 24 Ore Sanità, Dicembre 2006, 50.

Veritti D, Lanzetta P. La degenerazione maculare legata all'età. Scheda allegata a Sole 24 Ore Sanità, Febbraio 2007, 6.

Veritti D, Lanzetta P, Genovese U. La degenerazione maculare legata all'età. Utilizzo off-label dei farmaci: aspetti generali e risvolti per la terapia dell'AMD (prima parte). Scheda allegata a Sole 24 Ore Sanità, Aprile 2007, 14.

Veritti D, Lanzetta P, Genovese U. La degenerazione maculare legata all'età. Utilizzo off-label dei farmaci: aspetti generali e risvolti per la terapia dell'AMD (seconda parte). Scheda allegata a Sole 24 Ore Sanità, Maggio 2007, 19.

Veritti D, Lanzetta P. La degenerazione maculare legata all'età. Il trattamento dell'AMD: terapia fotodinamica con verteporfina e terapie combinate. Scheda allegata a Sole 24 Ore Sanità, Giugno 2007, 28.

Veritti D, Lanzetta P. La degenerazione maculare legata all'età. Ranibizumab e degenerazione maculare legata all'età. Scheda allegata a Sole 24 Ore Sanità, Settembre 2007, 36.

Lanzetta P, **Veritti D**, Dal Mas G. Nuove Tecniche di Fotocoagulazione Laser. Occhio alla Retina. 2010;2.

Veritti D, Dal Mas G, Lanzetta P. Triamcinolone acettonide in soluzione viscoelastica per via juxta-sclerale nel trattamento dell'edema maculare diabetico refrattario. Viscocirurgia. 2010;3:36-44.

Veritti D, Sarao V. Stem cells may be the next frontier for retinal disease. Ocular Surgery News Europe Edition. June 2011.

Veritti D, Gabai A. Development of eye played key role in evolutionary advantage. Ocular Surgery News Europe Edition. August 2011.

Veritti D, Macor S. Microaneurysms key in detecting diabetic retinopathy. Ocular Surgery News Europe Edition. September 2011.

Veritti D, Sarao V. Methods aim to decrease laser damage in treatment of retinal, choroidal conditions. Ocular Surgery News Europe Edition. October 2011.

Veritti D, Gabai A. Updated guidelines on use of anti-VEGF after treatment course for exudative AMD. Ocular Surgery News Europe Edition. December 2011.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D, Macor S. Study into pathology; treatment of epimacular membrane continues. Ocular Surgery News Europe Edition, January 2012.

Veritti D, Toneatto G. Dyes play vital role in vitreoretinal surgery. Ocular Surgery News Europe Edition, March 2012.

Gabai A, **Veritti D**. SLT may be a good first-choice treatment for glaucomatous eyes. Ocular Surgery News Europe Edition, May 2012.

TEACHING EXPERIENCE

Medical Biotechnology, Faculty of Medicine and Surgery, University of Udine, Italy. 2006
Taught: Gene Therapy and the Eye, Artificial Vision: Progress and Prospects.
Contact hours: 3. Twenty graduate students.

School of Nursing, Faculty of Medicine and Surgery, University of Udine, Italy. 2007
Taught: Cataract, Glaucoma, Postoperative Assistance in Ophthalmic Departments.
Contact hours: 4. Forty graduate students.

Medical Biotechnology, Faculty of Medicine and Surgery, University of Udine, Italy. 2007-2012
Taught: Gene Therapy and the Eye, Artificial Vision: Progress and Prospects, Corneal and Retinal Stem Cells.
Contact hours: 4. Fifteen graduate students.

Medical School, Faculty of Medicine and Surgery, University of Udine, Italy. 2010-present
Taught: Conjunctivitis and red eye, Glaucoma, Retinal detachment, Age-related macular degeneration, Retinal vein occlusion, diabetic retinopathy, cataract.
Contact hours: 6-12. Eighty graduate students.

RESIDENCY PROGRAM

Supervisor for the educational program of the University of Udine Ophthalmology Residency Program, Udine, Italy: 2012-present.

THESIS ASSISTANT SUPERVISOR

Giacomo Toneatto: "Chirurgia del pucker maculare mediante vitrectomia 25 gauge e peeling della membrana limitante interna verde di infracianina - assistito" Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2010.

Martina Santarelli: "Morphological and functional correlations before and after 25-gauge surgery for idiopathic macular pucker: A spectral domain OCT and microperimetric study". Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2011.

Manuel Pretato: "Membrane blue-dual e verde d'infracianina nel peeling della membrana limitante interna durante chirurgia 25-gauge per foro maculare idiopatico". Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2013.

Veronica Papa: "Confronto tra membrane blue-dual e verde d'infracianina nel peeling della membrana limitante interna durante chirurgia 25-gauge per pucker maculare idiopatico". Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2013.

Erica Maurutto: "Iniezioni intravitreali ed endoftalmiche, revisione della letteratura e analisi della casistica della Clinica Oculistica di Udine". Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2014.

Nestore Rota: "Trattamento del distacco retinico regmatogeno: tre tecniche chirurgiche a confronto". Corso di Laurea Specialistica in Medicina e Chirurgia. Università degli Studi di Udine; 2014.

PUBLISHED ABSTRACTS
AND CONFERENCE
PRESENTATIONS

Lanzetta P, Polito A, Roman Pognuz D, **Veritti D**. Detection of threshold and sub-threshold laser irradiation with optical coherence tomography. Invest Ophthalmol Vis Sci 2006 47: E-Abstract 5721.

Lanzetta P, **Veritti D**. Patient management in the era of anti-VEGF therapy. Presented at the Korean Retina Society meeting; November 30, 2007; Chungju, Korea.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D, Lanzetta P, Bandello F. Esperienza preliminare con il laser semiautomatico Pascal. Presented at the Annual Meeting of the "Società Italiana Laser in Oftalmologia"; January 25, 2008; Cortina d'Ampezzo, Italy.

Lanzetta P, **Veritti D**. Anti-VEGF multicentre trials: what have we learned?. Presented at the international symposium "Macula: Advances in diagnostic and Therapies"; February 8, 2008; Turin, Italy.

Lanzetta P, **Veritti D**. Anti-VEGF intravitreal injection: when and how?. Presented at the "27e Congrès de la Société Tunisienne d'Ophthalmologie"; March 7, 2008; Gammarth, Tunisia.

Lanzetta P, **Veritti D**. Il futuro della terapia della DMLE. Presented at "Retina 2008: Le degenerazioni maculari"; March 8, 2008; Rome, Italy.

Veritti D, Lanzetta P. Retinopatia diabetica, nuove terapie. Presented at "Retina 2008: Le degenerazioni maculari"; March 8, 2008; Rome, Italy.

Lanzetta P, **Veritti D**. Triple Therapy for Choroidal Neovascularization Due to Age-related Macular Degeneration. Ranibizumab, Intravitreal Triamcinolone Acetonide, and Verteporfin PDT. Early Vascular Changes. Presented at the Macula Society Annual Meeting; March 28, 2008; Palm Beach, FL, USA.

Veritti D, Lanzetta P, Bandello F. Posterior Juxtascleral Infusion of Modified Triamcinolone Acetonide Formulation for Refractory Diabetic Macular Edema: One-Year Follow-Up Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 3489.

Veritti D, Lanzetta P. Advances in Laser Photocoagulation. Presented at the course "Terapia Laser Classica della Retina"; May 17, 2008; Rome, Italy.

Lanzetta P, **Veritti D**. Off-label Avastin use: State of Experience. Presented at the EurCina Congress; May 23, 2008; Vienna, Austria.

Veritti D, Lanzetta P, Bandello F. Infusione juxtasclerale posteriore di triamcinolone acetone in nuova formulazione nel trattamento dell'edema maculare diabetico refrattario: 12 mesi di follow-up. Presented at the Annual Meeting of the "Società Oftalmologica Triveneta"; June 13, 2008; Trieste, Italy.

Veritti D, Lanzetta P. Juxtascleral Infusion of Triamcinolone Acetonide: a Clinical Case. Presented at the course: "Retinopatia Diabetica: dalla Diagnosi alla Terapia"; June 23, 2008; Bassano del Grappa, Italy.

Lanzetta P, **Veritti D**. Gli steroidi nel trattamento dell'edema maculare diabetico. Presented at the congress: "La macula diabetica, X edizione Giornate di Chirurgia Vitreo-retinica"; October 11, 2008; Monza, Italy.

Veritti D, Lanzetta P, Bandello F. Studio VITAL: Verteporfin, Triamcinolone Acetonide Juxtasclerale e Lucentis nella degenerazione maculare senile essudativa. Presented at the Annual Meeting of the "Società Italiana Laser in Oftalmologia"; January 30, 2009; Cortina d'Ampezzo, Italy.

Lanzetta P, **Veritti D**. Rôle de l'angiographie dans le diagnostic de l'œdème maculaire. Presented at the 28th Congress of the "Société tunisienne d'ophtalmologie"; March 13, 2009; Tunis, Tunisia.

Lanzetta P, **Veritti D**. Steroids and diabetic macular edema. Presented at the 28th Congress of the "Société tunisienne d'ophtalmologie"; March 13, 2009; Tunis, Tunisia.

Lanzetta P, **Veritti D**. New trends in Laser applications for retinal diseases. Presented at the 28th Congress of the "Société tunisienne d'ophtalmologie"; March 14, 2009; Tunis, Tunisia.

Veritti D, Lanzetta P. Guida ragionata all'uso degli antiangiogenici. Presented at the congress Retina 2009; March 28, 2009; Rome, Italy.

Zucchiatti I, **Veritti D**, Lanzetta P, Bandello F. Efficacy and Safety of Pascal Photocoagulator in the Treatment of Proliferative Diabetic Retinopathy. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 3, 2009; Fort Lauderdale, FL, USA.

Lanzetta P, **Veritti D**, Zucchiatti I, Savorgnan G, Drigo D, Bandello F. PASCAL Retinal Photocoagulation: Review of Parameters Applied in 1,242 Treatments. Presented at the Association for Re-

CURRICULUM VITAE
DANIELE VERITTI

search in Vision and Ophthalmology (ARVO) Annual Meeting; May 3, 2009; Fort Lauderdale, FL, USA.

Veritti D, Lanzetta P, Cascavilla ML, Drigo D, Bandello F. Triple Therapy for Choroidal Neovascularization Due to Age-Related Macular Degeneration. Ranibizumab, Modified Juxtasceral Triamcinolone Acetonide, and Verteporfin PDT. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 4, 2009; Fort Lauderdale, FL, USA.

Menchini F, Battaglia Parodi M, Polini G, **Veritti D**, Bandello F. Intravitreal Ranibizumab for Retinal Angiomatous Proliferation. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 4, 2009; Fort Lauderdale, FL, USA.

Lanzetta P, **Veritti D**. Drug Delivery. Presented at the congress Retina in Progress: Present and Future; June 4-6, 2009; Milan, Italy.

Lanzetta P, **Veritti D**. Macular Edema in Diabetic Retinopathy. Presented at the congress Retina in Progress: Present and Future; June 4-6, 2009; Milan, Italy.

Lanzetta P, **Veritti D**. Steroids in Diabetic Macular Edema. Presented at the congress Retina in Progress: Present and Future; June 4-6, 2009; Milan, Italy.

Lanzetta P, **Veritti D**. The Role of Inflammation in AMD. Presented at the congress Retina in Progress: Present and Future; June 4-6, 2009; Milan, Italy.

Lanzetta P, **Veritti D**. Ranibizumab. Presented at the congress Retina in Progress: Present and Future; June 4-6, 2009; Milan, Italy.

Lanzetta P, **Veritti D**, Dal Mas G. Nuove Tecniche di Fotocoagulazione Laser. Presented at the congress "Update sulla Retinopatia Diabetica"; February 12, 2010; Milan, Italy.

Veritti D. Desametasone nella Terapia dell'Edema Maculare Diabetico. Presented at the congress "Retinopatia Diabetica"; March 12, 2010; Reggio Emilia, Italy.

Veritti D. Le Ultime Novità. Presented at the congress "Retinopatia Diabetica"; March 12, 2010; Reggio Emilia, Italy.

Veritti D, Lanzetta P. Somministrazione di Medicinali nello Spazio Supracoroideale. Presented at the congress Retina 2010: Edema Retinico e Coroide; March 27, 2010; Rome, Italy.

Piermarocchi S, **Veritti D**, Maritan V, Lo Giudice G. Degenerazione Maculare Senile: Uso degli Anti-VEGF in Ospedale. Presented at the congress Argomenti controversi in Oftalmologia; April 10, 2010; Schio-Thiene, Italy.

Veritti D. Economics. Presented at the congress OCT e Degenerazione Maculare; April 16, 2010; Milan, Italy.

Veritti D. Un Caso di Edema Maculare. Presented at the congress Macular Advanced Multi-therapies Bologna; April 23, 2010; Bologna, Italy.

Veritti D, Sarao V, Savognani C, Polini G, Lanzetta P. Combination Therapy for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Anti-VEGF Monotherapy. Intravitreal Bevacizumab and Triamcinolone Acetonide. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 2, 2010; Fort Lauderdale, FL, USA.

Zucchiatti I, Savognani C, **Veritti D**, Battaglia Parodi M, Kontadakis DS, Papayannis A, Iacono P, Lanzetta P, Bandello F. Intravitreal Injection of Bevacizumab for Macular Edema Secondary to branch Retinal Vein Occlusion. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 4, 2010; Fort Lauderdale, FL, USA.

Veritti D. Retinopatia Diabetica. Presented at the congress Degenerazione Maculare Legata all'Età e Retinopatia Diabetica; May 28, 2010; Udine, Italy.

Veritti D. Terapia Combinata. Presented at the congress Retinopatia Diabetica 2010; June 3, 2010; Bassano del Grappa, Italy.

CURRICULUM VITAE
DANIELE VERITTI

Lanzetta P, **Veritti D**, Dal Mas G. Nuove Prospettive Terapeutiche della Degenerazione Maculare Legata all'Età di Tipo Secco. Presented at the congress Retina - Presente e Futuro; September 17, 2010; Naples, Italy.

Lanzetta P, **Veritti D**. Chirurgia 25 gauge del pucker maculare. Presented at the congress What's New 2010 Chirurgia Innovativa in Oftalmologia; September 24, 2010; Pordenone, Italy.

Lanzetta P, **Veritti D**. Il trattamento dell'edema maculare diabetico. Presented at the congress What's New 2010 Chirurgia Innovativa in Oftalmologia; September 24, 2010; Pordenone, Italy.

Veritti D. Occhio e micronutrizione. Presented at the congress Occhio, Dieta, Micronutrienti e Neuroprotezione; November 12, 2010; Udine, Italy.

Lanzetta P, **Veritti D**. Retinopatia diabetica: nuove terapie e supplementazione. Presented at the congress Occhio, Dieta, Micronutrienti e Neuroprotezione; November 12, 2010; Udine, Italy.

Lanzetta P, **Veritti D**. Is there still a role for combination therapy in neovascular AMD?. Presented at the 10th International AMD and Retina Congress; January 20, 2010; Lugano, Swiss.

Veritti D, Sarao V, Lanzetta P. Esperienza Preliminare con una piattaforma integrata lampada a fessura, OCT e fotocoagulatore laser. Presented at the Annual Meeting of the "Società Italiana Laser in Oftalmologia"; January 28, 2011; Cortina d'Ampezzo, Italy.

Lanzetta P, **Veritti D**. Diabetic macular edema treatment: what the evidence says and future perspectives. Presented at the congress "Present and future challenges of severe retinal diseases"; February 4, 2011; Verona, Italy.

Veritti D. Ranibizumab in the treatment of retinal vein occlusion. Presented at the congress "Nuove prospettive di trattamento nelle malattie occlusive della retina"; February 11, 2011; Reggio Emilia, Italy.

Lanzetta P, **Veritti D**. Avastin: what evidence available. Presented at "the 2nd World Congress on Controversies in Ophthalmology"; March 5, 2011; Barcelona, Spain.

Lanzetta P, **Veritti D**, Gabai A. 12-month treatment with intravitreal ranibizumab for wet AMD in a "real world" clinical setting. Presented at "the Macula Society 34th Annual Meeting"; March 11, 2011; Boca Raton, FL, USA.

Veritti D, Lanzetta P. Nuove terapie per l'atrofia geografica. Presented at the congress "Retina 2011: Nuove tecnologie, nuove terapie"; March 25, 2011; Rome, Italy.

Veritti D, Lanzetta P. Nuovi sistemi di somministrazione per le patologie retiniche. Presented at the congress "Retina 2011: Nuove tecnologie, nuove terapie"; March 25, 2011; Rome, Italy.

Veritti D, Toneatto G, Lanzetta P. Twenty-five Gauge Transconjunctival Sutureless Vitrectomy with Low-concentration Infracyanine Green-assisted Internal Limiting Membrane Peeling in Idiopathic Macular Pucker: Outcomes and Predictive Factors. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 4, 2011; Fort Lauderdale, FL, USA.

Sarao V, **Veritti D**, Lanzetta P. Real-time OCT Scanning During Sub-threshold Laser Irradiation. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 2, 2011; Fort Lauderdale, FL, USA.

Veritti D, Lanzetta P. Real-time OCT Scanning During Sub-threshold Laser Irradiation. Presented at the 33rd International Congress of Ophthalmology; May 14, 2011; Trieste, Italy.

Veritti D, Lanzetta P. Il trattamento dell'edema maculare diabetico: il ruolo dei farmaci corticosteroidi. Presented at the Congress Retinopatia Diabetica; June 3, 2011; Bassano del Grappa, Italy.

Veritti D, Lanzetta P. Effects of Intravitreal Anti-VEGF Agents on Retinal Morphology, Neovascular Network Size and Best Corrected Visual Acuity in Patients with Pigment Epithelium Detachment due to Occult Choroidal Neovascularization. Presented at the Retina Society Annual Meeting; September 3, 2011; Rome, Italy.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D. Etica e Pubblicazione. Presented at the Course Medical Writing; December 13, 2011; Padova, Italy.

Veritti D, Gabai A, Lanzetta P. Trabeculoplastica laser selettiva: una review della letteratura. Presented at the Annual Meeting of the "Società Italiana Laser in Oftalmologia"; January 26, 2012; Cortina d'Ampezzo, Italy.

Veritti D, Lanzetta P. Nuove terapie della DMLE atrofica. Presented at the congress Retina 2012: Retina Interna, Cellule Ganglionari e Ultime Terapie; March 31, 2012; Rome, Italy.

Veritti D, Lanzetta P. L'albero decisionale nella neovascolarizzazione da DMLE. Presented at the congress Retina 2012: Retina Interna, Cellule Ganglionari e Ultime Terapie; March 31, 2012; Rome, Italy.

Sarao V, **Veritti D,** Lanzetta P. Intravitreal Bevacizumab For Choroidal Neovascularization Due To Causes Other Than Age-related Macular Degeneration. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 9, 2012; Fort Lauderdale, FL, USA.

Lanzetta P, **Veritti D,** Sarao V. Twelve-month Treatment With Intravitreal Bevacizumab For Diabetic Macular Edema In A "Real World" Clinical Setting. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 6, 2012; Fort Lauderdale, FL, USA.

Veritti D, Santarelli M, Dal Mas G, Lanzetta P. Morphological and Functional Correlations Before and After 25-gauge Surgery for Idiopathic Macular Pucker. A Spectral Domain OCT and Microperimetric Study. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 7, 2012; Fort Lauderdale, FL, USA.

Veritti D. Potenzialità della H.E.L.P.-afèresi nel trattamento della degenerazione maculare legata all'età. Presented at the Course "Aggiornamento scientifico in medicina: indicazioni dell'afèresi terapeutica selettiva"; June 8, 2012; Desio, Italy.

Lanzetta P, **Veritti D.** The Management of Diabetic Macular Edema. Presented at the Euretina Annual Meeting; September 5, 2012; Milan, Italy.

Lanzetta P, **Veritti D.** The curious case of retinitis pigmentosa or Coats' disease or both. Presented at the Euretina Annual Meeting; September 7, 2012; Milan, Italy.

Lanzetta P, **Veritti D.** Role of subthreshold laser in DME. Presented at the Euretina Annual Meeting; September 9, 2012; Milan, Italy.

Veritti D, Lanzetta P. Combination Therapy in Neovascular Age-Related Macular Degeneration. 1st Joint Meeting of Pathology and Laboratory Diagnostics, 2012 September 12-15, Udine, Italy. Am J Pathol 2012; 181(Suppl):S1 Abstract AGE6.

Lanzetta P, **Veritti D.** Sistema digitale HD di registrazione e gestione di immagini in microchirurgia oculare. Confronto con tecnologia analogica. Presented at the Società Italiana Laser in Oftalmologia Annual Meeting; January 24, 2013; Cortina D'Ampezzo, Italy.

Sarao V, **Veritti D.** Bevacizumab intravitreale nel trattamento della neovascolarizzazione coroideale secondaria a degenerazione maculare miopica. Presented at the Società Italiana Laser in Oftalmologia Annual Meeting; January 25, 2013; Cortina D'Ampezzo, Italy.

Veritti D, Lanzetta P. Correzione della presbiopia e dell'ipermetropia mediante cheratoplastica ottimale. Presented at the Società Italiana Laser in Oftalmologia Annual Meeting; January 26, 2013; Cortina D'Ampezzo, Italy.

Veritti D. La gestione delle occlusioni venose retiniche: implicazioni per il medico e per il paziente legate al trattamento dell'edema maculare. Presented at the Course "Il paziente in primo piano. Malattie della superficie oculare, glaucoma e malattie della retina"; February 8, 2013; Udine, Italy.

Veritti D, Lanzetta P. Intravitreal injections: an healthcare failure modes and effects analysis. Presented at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT); March 8, 2013; Paris, France.

Veritti D. What's an appropriate dosing interval for intravitreal ranibizumab? A pharmacokinetic model. Presented at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT); March 8, 2013; Paris, France.

CURRICULUM VITAE
DANIELE VERITTI

Lanzetta P, **Veritti D.** Aflibercept for central retinal vein occlusion. Presented at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT); March 8, 2013; Paris, France.

Lanzetta P, **Veritti D.** Different drugs and regimens in the treatment of wet-AMD: what to choose?. Presented at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT); March 9, 2013; Paris, France.

Veritti D, Macor S, Lanzetta P. Effects of VEGF inhibition on vascularized pigment epithelium detachment due to occult choroidal neovascularization. Presented at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT); March 9, 2013; Paris, France.

Veritti D. Occhio rosso. Presented at the Course "Triage di pronto soccorso in oculistica"; April 10, 2013; Udine, Italy.

Veritti D. Occlusioni venose retiniche. Presented at the Course "Occhio agli anziani"; May 24, 2013; Udine, Italy.

Veritti D. Il ruolo dei corticosteroidi. Presented at the Course "Retinopatia Diabetica 2013"; June 1, 2013; Udine, Italy.

Veritti D. Nutraceutica, cibo e medicine. Presented at the Course "Nutraceutica e salute degli occhi"; June 21, 2013; Udine, Italy.

Veritti D. Il ruolo dell'infiammazione nell'edema maculare. Presented at the Course "Steroids in the treatment of retinal pathologies"; Nov 8, 2013; Udine, Italy.

Veritti D. Steroidi intravitreali nell'edema maculare diabetico. Presented at the Course "Steroids in the treatment of retinal pathologies"; Nov 8, 2013; Udine, Italy.

Veritti D. Degenerazione maculare legata all'età di tipo neovascolare: esperienza aflibercept in pazienti non-responder. Presented at the Società Italiana Laser in Oftalmologia Annual Meeting; January 31, 2014; Cortina D'Ampezzo, Italy.

Veritti D. Autofluorescenza del fondo oculare: ultime novità. Presented at the Course "Retina 2014"; March 28, 2014; Rome, Italy.

Veritti D. Epidemiologia e storia naturale della miopia patologica. Presented at the Course "Miopia patologica: quale futuro"; Apr 4, 2014; Udine, Italy.

Sarao V, **Veritti D,** Arias L, Lanzetta P. Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 6, 2014; Fort Lauderdale, FL, USA

Veritti D, Macor S, Lanzetta P. Early effects of dexamethasone erodible implant on macular edema due to retinal vein occlusion: retinal morphology and visual function. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 6, 2014; Fort Lauderdale, FL, USA

Veritti D. Discomfort da lente a contatto e film lacrimale.. Presented at the Course "Contattologia: cos'è importante?"; May 16, 2014; Udine, Italy.

Veritti D. Retina e miopia. Presented at the Società Oftalmologica Triveneta (SOT) Annual Meeting; Jun 13, 2014; Mestre (VE), Italy.

Veritti D. Approccio terapeutico ai pazienti con patologie oculari: ruolo degli anti-Tnf alfa e gestione dei pazienti affetti da patologie oculari e spondiloartriti (Spa). Presented at the Course "Approccio multidisciplinare ai pazienti con malattie infiammatorie muscolo scheletriche, gastrointestinali, oculari e dermatologiche. Il ruolo della terapia anti-tnf alfa"; Sep 12, 2014; Mortelegiano (UD), Italy.

Veritti D. Fisiopatologia dell'edema maculare diabetico. Presented at the Course "Retinopatia diabetica ed edema maculare: dallo screening alla terapia"; Sep 19, 2014; Udine, Italy.

Veritti D. Cefuroxima nelle prevenzioni dell'endofthalmit: valutazioni costo efficacia. Presented at the Course "What's new 2014"; Sep 26, 2014; Udine, Italy.

CURRICULUM VITAE
DANIELE VERITTI

Veritti D. Quali le evidenze in oftalmologia. Presented at the Course "Conservanti e farmaci generici: problemi e prospettive"; Nov 7, 2014; Udine, Italy.

Veritti D. L'edema maculare diabetico è una condizione infiammatoria? Presented at the Course "Edema maculare diabetico: il ruolo degli steroidi"; Nov 28, 2014; Udine, Italy.

Veritti D. La presenza della adesione vitreo-maculare influenza i risultati della terapia con anti-VEGF nei pazienti con DMLE neovascolare? revisione e metanalisi. Presented at the Società Italiana della Retina Annual Meeting; Feb 20, 2015; Venice, Italy.

Veritti D. Impianto intravitreale di desametasone nel trattamento dell'edema maculare diabetico: regime fisso o PRN?? revisione e metanalisi. Presented at the Società Italiana della Retina Annual Meeting; Feb 12, 2016; Venice, Italy.

Veritti D. Desametasone nell'edema maculare diabetico: rapidità dell'effetto e durata d'azione. Presented at the Course "Retina 2016"; Mar 3, 2016; Udine, Italy.

SURGICAL EXPERIENCE

Anterior segment procedures (first)

200

Anterior segment procedures (assistant)

300

Posterior segment procedures (assistant)

300

Laser treatments

400

Intravitreal injections

500

**PARTECIPATION IN
RESEARCH GROUPS**

Intravitreal ranibizumab for DME. Monthly PRN regimen. Outcomes and prognostic factors.

Role: Study organizer and coordinator (2012-present)

Institutions: Dept. of Ophthalmology University of Udine; Dept. of Ophthalmology University of Firenze; Dept. of Ophthalmology; University Vita-Sabote, Scientific Institute San Raffaele, Milan; G.B. Bietti Foundation for Study and Research in Ophthalmology, Rome; Dept. of Ophthalmology University of Trieste; Dept. of Ophthalmology University of Genova.

**PARTECIPATION IN
COLLABORATIVE
SPONSORED STUDIES**

Pazopanib eye drops in choroidal neovascularization due to AMD (MD7110852). Phase IIb.

Role: Study coordinator

Nevanac eye drops following cataract surgery in diabetic retinopathy patients (Mizar - C-09-003) Phase IIIb.

Role: Study coordinator

A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebocontrolled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy (FOV2304/GLIN/201/P), Phase II.

Role: Study coordinator

Long term safety and tolerability of 0.5 mg Fingolimod in patients with relapsing forms of multiple sclerosis. Phase III.

Role: OCT operator

A prospective observational study of ophthalmologic function in patients receiving Linezolid for two months or greater. Phase III.

Role: Subinvestigator

A 24-months, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections in patients with visual impairment due to macular edema secondary to central retinal vein occlusion. Phase IIb.

Role: Study coordinator

CURRICULUM VITAE
DANIELE VERITTI

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration. Phase IIIb.

Role: Subinvestigator

Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization. Phase III.

Role: Subinvestigator

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD. Phase IIIb.

Role: Subinvestigator

Ranibizumab 0.5mg in Myopic CNV. Phase IIIb.

Role: Subinvestigator

Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye. Phase IIIb.

Role: Subinvestigator

A Phase 3 Safety and Efficacy Study of Enoxima™ (E10030) Intravitreal Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy. Phase III.

Role: Subinvestigator

OTHER PROJECTS AND
ACTIVITIES

Cooking for all. Designing a kitchen for the visually impaired.

2009-2011

Rino Snidero Scientific Foundation

Progetto Olimpo: criteri e standard organizzativi dei centri per la diagnosi e la cura delle malattie della retina verso l'eccellenza.

Role: Local supervisor.

Dept. of Ophthalmology, University of Udine, Udine, Italy

2011-present

ASSOCIATIONS

PROFESSIONAL-SCIENTIFIC ASSOCIATIONS / PANELS

Association for Research in Vision and Ophthalmology (ARVO)

from Oct 2007

Società Italiana Laser in Oftalmologia (SILO)

from Jan 2008

European Retinal Panel (ERP)

2009-2013

Intravitreal Experts Group (IVEG)

from Dec 2011

Associazione Italiana Medici Oculisti (AIMO)

from Mar 2012

Gruppo Italiano di Angio-OCT (GLAO)

from Mar 2016

Società Oftalmologica Italiana (SOI)

from Mar 2016

NONPROFIT ASSOCIATIONS

Associazione Maculopatie Degenerative Onlus (AMD Onlus)

from 2006

I hereby authorize the use of my personal data, according to DLGS 196/2003.

I confirm I gained experience in the conduction of clinical trials in accordance with the principles of Good Clinical Practice.